Multitarget-directed drug design strategy: A novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects

Journal of Medicinal Chemistry

Volumn 49, Issue 23, 2006, Pages 6642-6645

  Antonello, Alessandra ^a   Tarozzi, Andrea ^a   Morroni, Fabiana ^a   Cavalli, Andrea ^a   Rosini, Michela ^a   Hrelia, Patrizia ^a   Bolognesi, Maria Laura ^a   Melchiorre, Carlo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PD 153053; THIOCTIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; COVALENT BOND; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; IC 50; MOLECULAR INTERACTION; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, MOLECULAR; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33751005304     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0608762     Document Type: Article

References (27)

1. Zhang, H. Y. One-compound-multiple-targets strategy to combat Alzheimer's disease. FEBS Lett. 2005, 579, 5260-5264.
2. Keith, C. T.; Borisy, A. A.; Stockwell, B. R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discovery 2005, 4, 71-78.
3. Bolognesi, M. L.; Minarini, A.; Tumiatti, V.; Melchiorre, C. Lipoic acid, a lead structure for multi-target-directed drugs for neurodegeneration. Mini-Rev. Med. Chem., in press.
4. Rosini, M.; Andrisano, V.; Bartolini, M.; Bolognesi, M. L.; Hrelia, P.; Minarini, A.; Tarozzi, A.; Melchiorre, C. Rational approach to discover multipotent anti-Alzheimer drugs. J. Med. Chem. 2005, 48, 360-363.
5. Matheson, S. L.; McNamee, J.; Jean-Claude, J. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J. Pharmacol. Exp. Ther. 2001, 296, 832-840.
6. Arora, A.; Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 2005, 315, 971-979.
7. Ranson, M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br. J. Cancer 2004, 90, 2250-2255.
8. El-Rayes, B. F.; LoRusso, P. M. Targeting the epidermal growth factor receptor. Br. J. Cancer 2004, 91, 418-424.
9. Wells, A. EGF receptor. Int. J. Biochem. Cell Biol. 1999, 31, 637-643.
10. Cohen, R. B. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin. Colorectal Cancer 2003, 2, 246-251.
11. Fry, D. W.; Bridges, A. J.; Denny, W. A.; Doherty, A.; Greis, K. D.; Hicks, J. L.; Hook, K. E.; Keller, P. R.; Leopold, W. R.; Loo, J. A.; McNamara, D. J.; Nelson, J. M.; Sherwood, V.; Smaill, J. B.; Trumpp-Kallmeyer, S.; Dobrusin, E. M. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12022-12027.
12. Smaill, J. B.; Rewcastle, G. W.; Loo, J. A.; Greis, K. D.; Chan, O. H.; Reyner, E. L.; Lipka, E.; Showalter, H. D.; Vincent, P. W.; Elliott, W. L.; Denny, W. A. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)-quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem. 2000, 43, 1380-1397.
13. Allen, L. F.; Eiseman, I. A.; Fry, D. W.; Lenehan, P. F. Cl-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin. Oncol. 2003, 30, 65-78.
14. Grandis, J. R.; Sok, J. C. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol. Ther. 2004, 102, 37-46.
15. Baselga, J.; Arteaga, C. L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 2005, 23, 2445-2459.
16. Valko, M.; Rhodes, C. J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 2006, 160, 1-40.
17. Mantovani, G.; Maccio, A.; Madeddu, C.; Mura, L.; Gramignano, G.; Lusso, M. R.; Murgia, V.; Camboni, P.; Ferreli, L.; Mocci, M.; Massa, E. The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radical Res. 2003, 37, 213-223.
18. Mantovani, G.; Maccio, A.; Madeddu, C.; Mura, L.; Massa, E.; Gramignano, G.; Lusso, M. R.; Murgia, V.; Camboni, P.; Ferreli, L. Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment. J. Environ. Pathol., Toxicol. Oncol. 2003, 22, 17-28.
19. van de Mark, K.; Chen, J. S.; Steliou, K.; Perrine, S. P.; Faller, D. V. Alpha-lipoic acid induces p27Kip-dependent cell cycle arrest in non-transformed cell lines and apoptosis in tumor cell lines. J. Cell. Physiol. 2003, 194, 325-340.
20. -.generation. Apoptosis 2005, 10, 359-368.
21. Tsou, H. R.; Mamuya, N.; Johnson, B. D.; Reich, M. F.; Gruber, B. C.; Ye, F.; Nilakantan, R.; Shen, R.; Discafani, C.; DeBlanc, R.; Davis, R.; Koehn, F. E.; Greenberger, L. M.; Wang, Y. F.; Wissner, A. 6-Substituted-4-(3- bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J. Med. Chem. 2001, 44, 2719-2734.
22. Antonello, A.; Hrelia, P.; Leonardi, A.; Marucci, G.; Rosini, M.; Tarozzi, A.; Tumiatti, V.; Melchiorre, C. Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds. J. Med. Chem. 2005, 48, 28-31.
23. Varkondi, E.; Schafer, E.; Bokonyi, G.; Gyokeres, T.; Orfi, L.; Petak, I.; Pap, A.; Szokoloczi, O.; Keri, G.; Schwab, R. Comparison of ELISA-based tyrosine kinase assays for screening EGFR inhibitors. J. Recept. Signal Transduction Res. 2005, 25, 45-56.
24. 2. Eur. J. Biochem. 2000, 267, 1933-1944.
25. Showalter, H. D.; Sercel, A. D.; Leja, B. M.; Wolfangel, C. D.; Ambroso, L. A.; Elliott, W. L.; Fry, D. W.; Kraker, A. J.; Howard, C. T.; Lu, G. H.; Moore, C. W.; Nelson, J. M.; Roberts, B. J.; Vincent, P. W.; Denny, W. A.; Thompson, A. M. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2́-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners. J. Med. Chem. 1997, 40, 413-426.
26. Ali, S.; El-Rayes, B. F.; Sarkar, F. H.; Philip, P. A. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol. Cancer Ther. 2005, 4, 1943-1951.
27. Domarkas, J.; Dudouit, F.; Williams, C.; Qiyu, Q.; Banerjee, R.; Brahimi, F.; Jean-Claude, B. J. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J. Med. Chem. 2006, 49, 3544-3552.